It's clear that there are multiple trials to consider in the name of brain cancer, some of them more recognized than others. However, it's clear that most of them are done over an extended stretch of time, seeing as how details are going to have to be picked up on. I feel as though this is for the best, seeing as how you can't exactly learn much over a day's time. This is especially true when considering the lengthy nature of study of the ETS2101 drug.
For those who do not know what the ETS2101 trial is, it entails a series of patients who have both primary and secondary brain cancer. According to an article on the Wall Street Journal, this procedure has been put into place for the sake of witnessing whether ETS2101 is safe for helping this condition or not. A certain dose has been applied and results have been surveyed to see if said dose is safe in addition to beneficial. The trial will continue on through 2014, which is something that organizations like Voices against Brain Cancer should make note of.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
It's easy to understand why these particular studies are done over the course of time, whether it is a matter of a few months or even a few years. Brain cancer is one of the most serious conditions and, as a result, a tremendous amount of focus is brought to the idea of treatment in the long run. Hopefully there is more work done with the ETS2101 drug set in place. In my opinion, there is a world of knowledge to pick up on here.
For those who do not know what the ETS2101 trial is, it entails a series of patients who have both primary and secondary brain cancer. According to an article on the Wall Street Journal, this procedure has been put into place for the sake of witnessing whether ETS2101 is safe for helping this condition or not. A certain dose has been applied and results have been surveyed to see if said dose is safe in addition to beneficial. The trial will continue on through 2014, which is something that organizations like Voices against Brain Cancer should make note of.
Of course, you may stop and wonder what exactly ETS2101 is. The article spoke about it and it's been said that it a drug commonly utilized in order to treat patients with trauma. Thanks to pharmacology, though, it's been believed that this drug can actually prove useful for the sake of helping cancer patients, too. Two studies are being done, one with primary cancer patients and the other entailing secondary cancer patients. To say that there has been quite a bit of time invested here would be an understatement.
With this procedure put into place, though, it's been said that patients have been given steadily higher doses over time until a tolerated level has been reached. Fifteen different patients have completed the studies and they were all given appropriate levels of the drug relative to body weight. The results have been positive, from what I have picked up on, as the tumors did not respond negatively to the drug. It's this level of success that, in my mind, can lead to further results down the road.
It's easy to understand why these particular studies are done over the course of time, whether it is a matter of a few months or even a few years. Brain cancer is one of the most serious conditions and, as a result, a tremendous amount of focus is brought to the idea of treatment in the long run. Hopefully there is more work done with the ETS2101 drug set in place. In my opinion, there is a world of knowledge to pick up on here.
About the Author:
Contact Voices Against Brain Cancer if you are seeking some more information about glioblastoma and brain cancer awareness.. This article, ETS2101 & Its Value To Brain Cancer is available for free reprint.
0 comments:
Post a Comment